Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
The US International Trade Commission (ITC) upheld its preliminary ruling saying that South Korean drugmaker Daewoong Pharmaceutical Co. copied the manufacturing process of a botulinum toxin strain by local rival Medytox Inc. in Medytox Medytox
Consequently, the US trade panel ordered a 21-month ban on imports of Daewoong Pharmaceutical's botulinum products into the US.
ITC's ruling, however, reduces the initial 10-year ban prescribed by the preliminary panel that ruled that Daewoong's misappropriated trade secrets belonging to Medytox.
Medytox Inc. claimed that Daewoong's Jeuveau was developed using a trade secret stolen from it that turns the deadly botulinum toxin into a wrinkle treatment.
Daewoong denied any theft allegations or that any trade secret was involved and argued the US agency is not the proper forum to decide on the dispute.
